Plain-English translation of NCT05371353 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is measuring how long your body's immune protection lasts after you complete a full series of the Recombination Quadrivalent HPV Vaccine (a vaccine that protects against four types of human papillomavirus). Researchers are collecting blood samples from women who already finished their vaccine doses to check whether their immunity remains strong over months and years. This information helps doctors understand how effective and durable this particular vaccine is.
The vaccine has been tested for safety and effectiveness, but researchers need to know how long the protection actually lasts in real patients — whether immunity stays strong indefinitely or gradually fades over time. Understanding this helps guide future vaccination recommendations and booster schedules.
You likely qualify if…
You likely don't qualify if…
Since you have already completed your three-dose vaccine series, your participation involves giving blood samples at scheduled follow-up visits over an extended period. The study team will measure antibodies (immune proteins) in your blood to see how well your body has maintained its protection against the virus. You'll be asked to return for visits according to the study schedule and answer questions about your health.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
Shanghai Bovax Biotechnology Co., Ltd.
Enrollment target
~600 participants
Started
May 2022
Primary completion
May 2027
Age range
9 Years – 45 Years
Sex
Female only
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jikai Zhang
Guangdong Center for Disease Prevention and Control
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.